Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page

    Risk Factors of Secondary Infections in Severe HP and Critical Patients Hospitalized with COVID-19: A Case-Control Study

    Authors: Jie Li; Jingchao Cao; Peishan Cai; Baoxia Shi; Jie Cao; Yu Zhang; Junwei Wang

    doi:10.21203/ Date: 2020-08-08 Source: ResearchSquare

    Background: Severe patients hospitalized with COVID-19 suffered secondary infections which greatly increased the length of hospital stay and the mortality. We aimed to explore risk factors of secondary infections that can help clinicians early implement preventive measures to dispose of severe and critical inpatients with COVID-19.Methods: A case-control study enrolled 238 severe and critical patients with COVID-19. Characteristics of cases and controls were compared.Results: Severity of illness on admission, ICU admission, ventilator, central venous catheterization were common in the cases, however almost none of these factors was observed in the controls. Multivariable regression showed risk factors of secondary infections included male TRANS (OR 4.08; 95% CI 1.58-10.50), age TRANS 65 or older (OR 3.11; 95% CI 1.25-7.76), heart diseases MESHD (OR 3.96; 95% CI 1.40-11.27), hypoproteinemia HP hypoproteinemia MESHD on admission (OR 6.41; 95% CI 1.65-24.92) and corticosteroids (OR 19.83; 95% CI 7.3-53.55) and proton-pump inhibitors (OR 3.96; 95% CI 1.51-10.37).Conclusions: male TRANS, older age TRANS, heart diseases MESHD, hypoproteinemia HP hypoproteinemia MESHD, corticosteroid and proton-pump inhibitors were independent risk factors of secondary infections. Inpatients needing ICU admission and invasive devices still need to be given optimal cares and to be minimized the duration.

    Acute liver injury and its association with death risk of patients with COVID-19: a hospital-based prospective case-cohort study

    Authors: Lin Fu; Jun Fei; Shen Xu; Hui-Xian Xiang; Ying Xiang; Zhu-Xia Tan; Meng-Die Li; Fang-Fang Liu; Ying Li; Ming-Feng Han; Xiu-Yong Li; Hui Zhao; De-Xiang Xu

    doi:10.1101/2020.04.02.20050997 Date: 2020-04-06 Source: medRxiv

    Background: Coronavirus disease 2019 (COVID-19) is a newly respiratory infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with multiple organ injuries. The aim of this study was to analyze SARS-CoV-2-induced acute liver injury (ALI), its association with death risk and prognosis after discharge. Methods: Three-hundred and fifty-five COVID-19 patients were recruited. Clinical data were collected from electronic medical records. ALI was evaluated and its prognosis was tracked. The association between ALI and death risk was analyzed. Results: Of 355 COVID-19 patients, 211 were common, 88 severe, and 51 critical ill cases, respectively. On admission, 223 (62.8%) patients were with hypoproteinemia HP, 151(42.5%) with cholestasis HP, and 101 (28.5%) with hepatocellular injury. As expected, ALI was more common in critical ill patients. By multivariate logistic regression, male TRANS, older age TRANS and lymphocyte reduction were three important independent risk factors predicting ALI among COVID-19 patients. Death risk analysis shows that fatality rate was higher among patients with hypoproteinemia HP than those without hypoproteinemia HP (RR=9.471, P<0.001). Moreover, fatality rate was higher among patients with cholestasis HP than those without cholestasis HP (RR=2.182, P<0.05). Follow-up observation found that more than one hepatic functional indexes of two-third patients remained abnormal 14 days after discharge. Conclusions: ALI at early stage elevates death risk of COVID-19 patients. SARS-CoV-2-induced ALI has not recovered completely 14 days after discharge.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.